Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovascular disease (ASCVD) and other diseases ...
Combined Company to Trade on Nasdaq Under Ticker œTRMLTalaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq:...
Talaris CGT plants bulk out NYBCe CDMO biz
Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE)...
Talaris Therapeutics has entered a definitive agreement to merge with late-stage clinical biotechnology company Tourmaline Bio.
Talaris Therapeutics’ plans have crystallized. Having stopped its transplant programs and hunkered down, the biotech has now entered into a reverse merger that will provide Tourmaline Bio with a platform for taking an ex-Pfizer drug into midphase clinical trials.
Talaris Therapeutics will hand over its spot on the Nasdaq to Tourmaline Bio in a reverse merger to fund trials of an ex-Pfizer drug it hopes can compete with Horizon Therapeutics and Immunovant.
BOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and...
Talaris Therapeutics was already put on life support back in February, when the biotech axed two kidney transplant trials along with a third of its staff. Now, the company is letting go of 95% of remaining employees.
Talaris Therapeutics said it will be stopping two clinical trials of its stem cell therapy, meant to reduce the need for immunosuppression in kidney transplant patients.